Definitive Contract 75N93024C00002
Award Date
11/17/23
Potential Completion Date
11/16/30
Potential Value
$22M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Mriglobal
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Potomac, MD 20850, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
2
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $13,047,673.64 definitive cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Mriglobal (doing business as Midwest Research Institute), a 501(c)(3) not-for-profit research organization. The contract is for the Mycobacterium Tuberculosis (MTB) Quality Assessment Program (TBQA), with a period of performance through December 31, 2023. This contract was not set aside for any specific business type. Mriglobal...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, awarded a $7,224,693.00 definitive cost contract to the Translational Genomics Research Institute (TGen), a non-profit biomedical research organization. The contract is for "MYCOBACTERIUM TUBERCULOSIS PROTEOME-WIDE EPITOPE DISCOVERY AND HOST TRANSCRIPTOME-WIDE T CELL PHENOTYPING IN HIGH DISEASE BURDEN POPULATIONS" and has an ultimate completion date of September 29, 2025. The contract does not have...
The National Institute of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Intramural Research Program (IRP), Laboratory of Clinical Immunology and Microbiology Tuberculosis Research Section awarded a $362,671.10 firm fixed price delivery order contract to Medical Science & Computing, LLC to provide support for Predict Tuberculosis P. The contract has a period of performance starting July 17, 2023 through July 16, 2024 and will be performed in South Africa.
This is a $13,523,501.30 definitive contract awarded by the Centers for Disease Control and Prevention (CDC) to The Research Institute Of The Mcgill University Health Centre for Tuberculosis Trials Consortium Services. The contract has a period of performance through December 31, 2030 and was awarded on January 1, 2021. It is a cost-no-fee contract to support clinical trials and research on the treatment, diagnosis, and prevention of tuberculosis, including studies of latent TB infection in...
This is a $795,971.00 cost-plus-fixed-fee delivery order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency, to Mriglobal, doing business as Midwest Research Institute, a 501(c)(3) non-profit research organization. The contract is for the process development of the tuberculosis treatment drug Telacebec, and involves the exercise of options 1-4. This contract was not set aside for any specific business category. Mriglobal holds multiple...
This is a delivery order awarded to Mriglobal, doing business as Midwest Research Institute, under a $3,500.00 Firm Fixed Price Indefinite Delivery/Indefinite Quantity (IDIQ) contract. The contract was awarded by the National Institute of Allergy and Infectious Diseases, a civilian agency, for the Diagnostics Pre-Clinical Services Program. The contract has a period of performance through June 19, 2030. Mriglobal is a 501(c)(3) not-for-profit research organization that provides scientific...
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $110,000.00 firm fixed price purchase order to the National Institute for Research in Tuberculosis in India. The order is for unspecified "other functions" related to tuberculosis research. The award does not have a set-aside designation and was completed on January 27, 2014. The National Institute for Research in Tuberculosis is an international non-profit organization that has previously participated...
This is a delivery order awarded under a $3,500,000 indefinite-delivery, indefinite-quantity (IDIQ) contract with the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services. The contract is for the Diagnostics Pre-Clinical Services Program and is a firm fixed-price arrangement. The prime contractor is Mriglobal, a 501(c)(3) not-for-profit research organization that provides scientific research, testing, training, and product...
This federal contract was awarded by a U.S. government agency to the National Institute For Research In Tuberculosis, a non-profit organization that operates as a hospital and conducts research on tuberculosis. The contract, valued at $100,000.00, is a purchase order that does not have a set-aside designation. The contract is for the provision of specialized medical services, facilities, staff expertise, and access to patient populations to enable research on tuberculosis treatment and disease...
This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to The Global Alliance For TB Drug Development Inc., a non-profit organization. The $9,851,406.00 cost-no-fee contract is for the development of a novel modulator targeting proteostasis for the treatment of M. tuberculosis, with a completion date of April 30, 2028. The contract was awarded under NIAID's Broad...